Optimising the heart failure treatment pathway: the role of SGLT2 inhibitors.
Author
Evans, MarcMorgan, Angharad R
Yousef, Zaheer
Ellis, Gethin
Dashora, Umesh
Patel, Dipesh C
Brown, Pam
Hanif, Wasim
Townend, Johnathan N
Kanumilli, Naresh
Moore, Jim
Wilding, John P H
Bain, Stephen C
Publication date
2021-06-23Subject
Diabetes
Metadata
Show full item recordAbstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were first developed as glucose-lowering therapies for the treatment of diabetes. However, these drugs have now been recognised to prevent worsening heart-failure events, improve health-related quality of life, and reduce mortality in people with heart failure with reduced ejection fraction (HFrEF), including those both with and without diabetes. Despite robust clinical trial data demonstrating favourable outcomes with SGLT2 inhibitors for patients with HFrEF, there is a lack of familiarity with the HF indication for these drugs, which have been the remit of diabetologists to date. In this article we use consensus expert opinion alongside the available evidence and label indication to provide support for the healthcare community treating people with HF regarding positioning of SGLT2 inhibitors within the treatment pathway. By highlighting appropriate prescribing and practical considerations, we hope to encourage greater, and safe, use of SGLT2 inhibitors in this population.Citation
Evans M, Morgan AR, Yousef Z, Ellis G, Dashora U, Patel DC, Brown P, Hanif W, Townend JN, Kanumilli N, Moore J, Wilding JPH, Bain SC. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs. 2021 Jul;81(11):1243-1255. doi: 10.1007/s40265-021-01538-6. Epub 2021 Jun 23Type
ArticleAdditional Links
https://link.springer.com/journal/40265PMID
34160822Journal
DrugsPublisher
Springer Internationalae974a485f413a2113503eed53cd6c53
10.1007/s40265-021-01538-6